The Hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein 1 in ovarian cancer

Zhang,Hong; Hu,Lanyan; Cheng,Minzhang; Wang,Qian; Hu,Xinyue; Chen,Qi

doi:10.3892/or.2020.7798

The Hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein 1 in ovarian cancer

Authors:
- Hong Zhang
- Lanyan Hu
- Minzhang Cheng
- Qian Wang
- Xinyue Hu
- Qi Chen
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Center for Experimental Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Published online on: October 9, 2020 https://doi.org/10.3892/or.2020.7798
Pages: 2610-2620
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Various studies have revealed that the Hedgehog (Hh) signaling pathway promotes ovarian cancer invasion, migration and drug resistance. Previous studies by our group have identified a set of genes, including multidrug resistance gene 1 (MDR1), that are regulated by Hh signaling in ovarian cancer. However, the association between Hh signaling activation and MDR1 expression requires further validation. In the present study, reverse transcription‑quantitative PCR or western blot assays were used to evaluate the mRNA and protein expression levels of MDR1, Sonic Hh (Shh), glioma‑associated oncogene 2 (Gli2), Gli1 and γ‑phosphorylated H2A.X variant histone (γ‑H2AX). MTT and colony‑formation assays were performed to determine the effect of cisplatin (DDP) after inhibiting the Hh pathway in ovarian cancer cells. The results indicated that MDR1, Gli2 and Shh levels were much higher in SK‑OV‑3 cells with acquired DDP resistance than in native SK‑OV‑3 cells. ES‑2 cells with overexpression of Gli2 were capable of efficiently forming colonies in the presence of low DDP concentrations. By contrast, Gli2 knockdown in SK‑OV‑3 cells decreased the colony‑forming ability under the same concentration of DDP. As determined by MTT assays, knockdown of Gli2 or targeting of the Hh signaling pathway with either Gli‑antagonist 61 (GANT61) or cyclopamine, in combination with DDP treatment, diminished the viability of ES‑2 and SK‑OV‑3 cells, whereas Gli2 overexpression increased the viability of ES‑2 cells in the presence of DDP. Knockdown of Gli2 or targeting the Hh signaling pathway with GANT61 also increased γ‑H2AX levels but decreased the expression of MDR1 in the presence of DDP. MDR1 expression is regulated by the Hh signaling pathway and is likely a downstream transcription factor of Gli2. In conclusion, targeting the Hh signaling pathway increases the sensitivity of ovarian cancer to DDP. MDR1 is a target gene of the Hh signaling pathway and this pathway may affect chemoresistance of ovarian cancer to DDP via MDR1.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Nüsslein-Volhard C and Wieschaus E: Mutations affecting segment number and polarity in Drosophila. Nature. 287:795–801. 1980. View Article : Google Scholar : PubMed/NCBI
4	Ingham PW and McMahon AP: Hedgehog signaling in animal development_ paradigms and princip. Genes Dev. 15:3059–3087. 2001. View Article : Google Scholar : PubMed/NCBI
5	Hui CC and Angers S: Gli proteins in development and disease. Annu Rev Cell Dev Biol. 27:513–537. 2011. View Article : Google Scholar : PubMed/NCBI
6	Bakshi A, Chaudhary SC, Rana M, Elmets CA and Athar M: Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond. Mol Carcinog. 56:2543–2557. 2017. View Article : Google Scholar : PubMed/NCBI
7	Park KS, Martelotto LG, Peifer M, Sos ML, Karnezis AN, Mahjoub MR, Bernard K, Conklin JF, Szczepny A, Yuan J, et al: A crucial requirement for hedgehog signaling in small cell lung cancer. Nat Med. 17:1504–1508. 2011. View Article : Google Scholar : PubMed/NCBI
8	Li H, Li J and Feng L: Hedgehog signaling pathway as a therapeutic target for ovarian cancer. Cancer Epidemiol. 40:152–157. 2016. View Article : Google Scholar : PubMed/NCBI
9	Song X, Yan L, Lu C, Zhang C, Zhu F, Yang J, Jing H, Zhang Y, Qiao J and Guo H: Activation of hedgehog signaling and its association with cisplatin resistance in ovarian epithelial tumors. Oncol Lett. 15:5569–5576. 2018.PubMed/NCBI
10	Steg AD, Katre AA, Bevis KS, Ziebarth A, Dobbin ZC, Shah MM, Alvarez RD and Landen CN: Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol Cancer Ther. 11:1587–1597. 2012. View Article : Google Scholar : PubMed/NCBI
11	Liao X, Siu MK, Au CW, Wong ES, Chan HY, Ip PP, Ngan HY and Cheung AN: Aberrant activation of hedgehog signaling pathway in ovarian cancers: Effect on prognosis, cell invasion and differentiation. Carcinogenesis. 30:131–140. 2009. View Article : Google Scholar : PubMed/NCBI
12	Ben-Hamo R, Zilberberg A, Cohen H, Bahar-Shany K, Wachtel C, Korach J, Aviel-Ronen S, Barshack I, Barash D, Levanon K and Efroni S: Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types. NPJ Precis Oncol. 3:122019. View Article : Google Scholar : PubMed/NCBI
13	Zhang J, Li ZY, Duan XJ, Fan XM, Liu WN and Li YH: Clinical significance of FOXM1 and gli-1 protein expression in high-grade ovarian serous carcinoma. Zhonghua Zhong Liu Za Zhi. 38:904–908. 2016.(In Chinese). PubMed/NCBI
14	Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, et al: FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. J Exp Clin Cancer Res. 36:632017. View Article : Google Scholar : PubMed/NCBI
15	Meng E, Hanna A, Samant RS and Shevde LA: The impact of hedgehog signaling pathway on DNA repair mechanisms in human cancer. Cancers (Basel). 7:1333–1348. 2015. View Article : Google Scholar : PubMed/NCBI
16	Huang RL, Gu F, Kirma NB, Ruan J, Chen CL, Wang HC, Liao YP, Chang CC, Yu MH, Pilrose JM, et al: Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers. Epigenetics. 8:624–634. 2014. View Article : Google Scholar
17	Ke Z, Caiping S, Qing Z and Xiaojing W: Sonic hedgehog-gli1 signals promote epithelial-mesenchymal transition in ovarian cancer by mediating PI3K/AKT pathway. Med Oncol. 32:3682015. View Article : Google Scholar : PubMed/NCBI
18	Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M and Landen CN: Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res. 18:869–881. 2012. View Article : Google Scholar : PubMed/NCBI
19	Bossennec M, Di Roio A, Caux C and Ménétrier-Caux C: MDR1 in immunity: Friend or foe? Oncoimmunology. 7:e14993882018. View Article : Google Scholar : PubMed/NCBI
20	Lu L, Katsaros D, Wiley A, de la Longrais IA, Puopolo M and Yu H: Expression of MDR1 in epithelial ovarian cancer and its association with disease progression. Oncol Res. 16:395–403. 2007. View Article : Google Scholar : PubMed/NCBI
21	Vaidyanathan A, Sawers L, Gannon AL, Chakravarty P, Scott AL, Bray SE, Ferguson MJ and Smith G: ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer. 115:431–441. 2016. View Article : Google Scholar : PubMed/NCBI
22	Cui D, Xu Q, Wang K and Che X: Gli1 is a potential target for alleviating multidrug resistance of gliomas. J Neurol Sci. 288:156–166. 2010. View Article : Google Scholar : PubMed/NCBI
23	Chen Q, Xu R, Zeng C, Lu Q, Huang D, Shi C, Zhang W, Deng L, Yan R, Rao H, et al: Down-Regulation of gli transcription factor leads to the inhibition of migration and invasion of ovarian cancer cells via integrin beta4-mediated FAK signaling. PLoS One. 9:e883862014. View Article : Google Scholar : PubMed/NCBI
24	Zhang H, Wang Y, Chen T, Zhang Y, Xu R, Wang W, Cheng M and Chen Q: Aberrant activation of hedgehog signalling promotes cell migration and invasion via matrix metalloproteinase-7 in ovarian cancer cells. J Cancer. 10:990–1003. 2019. View Article : Google Scholar : PubMed/NCBI
25	Roessler E, Ermilov AN, Grange DK, Wang A, Grachtchouk M, Dlugosz AA and Muenke M: A previously unidentified amino-terminal domain regulates transcriptional activity of wild-type and disease-associated human GLI2. Hum Mol Genet. 14:2181–2188. 2005. View Article : Google Scholar : PubMed/NCBI
26	Wang D, Hu G, Du Y, Zhang C, Lu Q, Lv N and Luo S: Aberrant activation of hedgehog signaling promotes cell proliferation via the transcriptional activation of forkhead Box M1 in colorectal cancer cells. J Exp Clin Cancer Res. 36:232017. View Article : Google Scholar : PubMed/NCBI
27	Yan R, Peng X, Yuan X, Huang D, Chen J, Lu Q, Lv N and Luo S: Suppression of growth and migration by blocking the hedgehog signaling pathway in gastric cancer cells. Cell Oncol (Dordr). 36:421–435. 2013. View Article : Google Scholar : PubMed/NCBI
28	Guo P, Peng D, Xiong X and Zhang S: Expression of microRNA-100 and its correlation with drug resistance in human ovarian cancer SKOV3/DDP cells. Nan Fang Yi Ke Da Xue Xue Bao. 35:1624–1627. 2015.(In Chinese). PubMed/NCBI
29	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
30	Wang Q, Shi YL, Zhou K, Wang LL, Yan ZX, Liu YL, Xu LL, Zhao SW, Chu HL, Shi TT, et al: PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death Dis. 9:7392018. View Article : Google Scholar : PubMed/NCBI
31	Gao ZJ, Yuan WD, Yuan JQ, Yuan K and Wang Y: Downregulation of HIF-2alpha reverse the chemotherapy resistance of lung adenocarcinoma A549 cells to cisplatin. Med Sci Monit. 24:1104–1111. 2018. View Article : Google Scholar : PubMed/NCBI
32	Reed E, Larkins TL, Chau CH and Figg WD: DNA repair: ERCC1, nucleotide excision repair, and platinum resistance. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Cancer Drug Discovery and Development. Rudek MA, et al: Springer Science and Business Media; New York: DOI 10.1007/978-1-4614-9135-4_18; pp. 333–349. 2014, View Article : Google Scholar
33	Ding Y, Niu W, Zhang T, Wang J, Cao J, Chen H, Wang R and An H: Levistolide A synergistically enhances doxorubicininduced apoptosis of k562/dox cells by decreasing MDR1 expression through the ubiquitin pathway. Oncol Rep. 41:1198–1208. 2018.PubMed/NCBI
34	Zeng C, Chen T, Zhang Y and Chen Q: Hedgehog signaling pathway regulates ovarian cancer invasion and migration via adhesion molecule CD24. J Cancer. 8:786–792. 2017. View Article : Google Scholar : PubMed/NCBI
35	Wiechert A, Saygin C, Thiagarajan PS, Rao VS, Hale JS, Gupta N, Hitomi M, Nagaraj AB, DiFeo A, Lathia JD and Reizes O: Cisplatin induces stemness in ovarian cancer. Oncotarget. 7:30511–30522. 2016. View Article : Google Scholar : PubMed/NCBI
36	Barakat MT, Humke EW and Scott MP: Learning from jekyll to control hyde: Hedgehog signaling in development and cancer. Trends Mol Med. 16:337–348. 2010. View Article : Google Scholar : PubMed/NCBI
37	Steg AD, Burke MR, Amm HM, Katre AA, Dobbin ZC, Jeong DH and Landen CN: Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer. Oncotarget. 5:7065–7080. 2014. View Article : Google Scholar : PubMed/NCBI
38	Ding J, Zhou XT, Zou HY and Wu J: Hedgehog signaling pathway affects the sensitivity of hepatoma cells to drug therapy through the ABCC1 transporter. Lab Invest. 97:819–832. 2017. View Article : Google Scholar : PubMed/NCBI
39	Chaudary N, Pintilie M, Hedley D, Hill RP, Milosevic M and Mackay H: Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts. Br J Cancer. 116:50–57. 2017. View Article : Google Scholar : PubMed/NCBI
40	Yu B, Gu D, Zhang X, Li J, Liu B and Xie J: GLI1-Mediated regulation of side population is responsible for drug resistance in gastric cancer. Oncotarget. 8:27412–27427. 2017. View Article : Google Scholar : PubMed/NCBI
41	Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E, et al: The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature. 511:90–93. 2014. View Article : Google Scholar : PubMed/NCBI
42	Amable L: Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 106:27–36. 2016. View Article : Google Scholar : PubMed/NCBI
43	Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F and Reed E: Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res. 20:645–652. 2000.PubMed/NCBI
44	Laner-Plamberger S, Kaser A, Paulischta M, Hauser-Kronberger C, Eichberger T and Frischauf AM: Cooperation between GLI and JUN enhances transcription of JUN and selected GLI target genes. Oncogene. 28:1639–1651. 2009. View Article : Google Scholar : PubMed/NCBI
45	Kudo K, Gavin E, Das S, Amable L, Shevde LA and Reed E: Inhibition of gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair. Oncogene. 31:4718–4724. 2012. View Article : Google Scholar : PubMed/NCBI
46	Agyeman A, Mazumdar T and Houghton JA: Regulation of DNA damage following termination of hedgehog (HH) survival signaling at the level of the GLI genes in human colon cancer. Oncotarget. 3:854–868. 2012. View Article : Google Scholar : PubMed/NCBI
47	Li J, Cai J, Zhao S, Yao K, Sun Y, Li Y, Chen L, Li R, Zhai X, Zhang J and Jiang C: GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment. J Exp Clin Cancer Res. 35:1842016. View Article : Google Scholar : PubMed/NCBI
48	Kuo LJ and Yang LX: γ-H2AX-a novel biomarker for DNA double-strand breaks. In Vivo. 22:305–310. 2008.PubMed/NCBI